Modulation of apolipoprotein c-III expression
AssigneeIsis Pharmaceuticals, Inc.
InventorsRosanne M. Crooke, Mark J. Graham, Kenneth W. Dobie
Life of this patent
Estimating the term…
Abstract
Compounds, compositions and methods are provided for modulating the expression of apolipoprotein C-III. The compositions comprise oligonucleotides, targeted to nucleic acid encoding apolipoprotein C-III. Methods of using these compounds for modulation of apolipoprotein C-III expression and for diagnosis and treatment of disease associated with expression of apolipoprotein C-III are provided.
Claims18
A compound comprising a modified oligonucleotide consisting of 12 to 30 linked nucleosides comprising an at least 8 consecutive nucleobase portion complementary to an equal number of nucleobases of nucleotides 3533-3552 of SEQ ID NO:
- 4, wherein said modified oligonucleotide is at least 90% complementary to SEQ ID NO:
- 4.
A modified oligonucleotide consisting of 20 linked nucleosides comprising the nucleobase sequence of SEQ ID NO:
- 87 and:
- a gap segment consisting of ten linked deoxynucleosides;
- a 5′ wing segment consisting of five linked nucleosides;
- a 3′ wing segment consisting of five linked nucleosides;
- wherein the gap segment is positioned between the 5′ wing segment and the 3′ wing segment, wherein each nucleoside of each wing segment comprises a 2′-O-methoxyethyl sugar, wherein each internucleoside linkage of said modified oligonucleotide is a phosphorothioate linkage, and wherein each cytosine residue of said modified oligonucleotide is a 5-methylcytosine.
Dependencies are inferred from the claim text.